| Bioactivity | RTC-30 is an optimized phenothiazine with anti-cancer potency. RTC-30 contains a hydroxylated linker (N) that confers increased oral bioavailability[1]. | ||||||||||||
| Invitro | RTC-30 (0-40 μM; 48 hours) inhibits H1650 lung adenocarcinoma cell growth with an GI50 of 15 μM[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | RTC-30 | ||||||||||||
| CAS | 1423077-95-5 | ||||||||||||
| Formula | C24H23F3N2O4S | ||||||||||||
| Molar Mass | 492.51 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kastrinsky DB, et al. Reengineered tricyclic anti-cancer agents. Bioorg Med Chem. 2015 Oct 1;23(19):6528-34. |
RTC-30
CAS: 1423077-95-5 F: C24H23F3N2O4S W: 492.51
RTC-30 is an optimized phenothiazine with anti-cancer potency. RTC-30 contains a hydroxylated linker (N) that confers in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.